{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:39:37Z","timestamp":1761946777848},"reference-count":30,"publisher":"Impact Journals, LLC","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,8,30]]},"DOI":"10.18632\/oncotarget.9809","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T18:01:08Z","timestamp":1464976868000},"page":"57310-57316","source":"Crossref","is-referenced-by-count":19,"title":["A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma"],"prefix":"10.18632","volume":"7","author":[{"given":"Chuanhua","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of GI Oncology, 307 Hospital of PLA, Academy of Military Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of GI Oncology, 307 Hospital of PLA, Academy of Military Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of GI Oncology, 307 Hospital of PLA, Academy of Military Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of GI Oncology, 307 Hospital of PLA, Academy of Military Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuling","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of GI Oncology, 307 Hospital of PLA, Academy of Military Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feijiao","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of GI Oncology, 307 Hospital of PLA, Academy of Military Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of GI Oncology, 307 Hospital of PLA, Academy of Military Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of GI Oncology, 307 Hospital of PLA, Academy of Military Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of GI Oncology, 307 Hospital of PLA, Academy of Military Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of GI Oncology, 307 Hospital of PLA, Academy of Military Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,6,3]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1470-2045(07)70172-9","article-title":"Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities","volume":"8","author":"Triboulet","year":"2007","journal-title":"Lancet Oncol"},{"key":"2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","article-title":"Oesophageal carcinoma","volume":"381","author":"Luketich","year":"2013","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1200\/JCO.2014.59.7765","article-title":"Controversies in the treatment of local and locally advanced gastric and esophageal cancers","volume":"33","author":"Leichman","year":"2015","journal-title":"J Clin Oncol"},{"key":"4","first-page":"156","article-title":"Current strategies in chemoradiation for esophageal cancer","volume":"5","author":"Chang","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"5","first-page":"106","article-title":"Paclitaxel in the treatment of esophageal cancer","volume":"26","author":"Weiner","year":"1999","journal-title":"Semin Oncol"},{"key":"6","first-page":"489","article-title":"Radiosensitizing Effect of Weekly-dose Paclitaxel on Locally Advanced Esophageal Carcinoma","volume":"6","author":"Jianjun","year":"2012","journal-title":"Zhong Liu Ji Chu Yu Lin Chuang"},{"key":"7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000132393","article-title":"Epidermal growth factor receptor-directed therapy in esophageal cancer","volume":"73","author":"Javle","year":"2007","journal-title":"Oncology"},{"key":"8","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/ijc.21512","article-title":"Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer","volume":"118","author":"Scher\u00fcbl","year":"2006","journal-title":"Int J Cancer"},{"key":"9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fonc.2012.00031","article-title":"Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence","volume":"2","author":"Mehta","year":"2012","journal-title":"Front Oncol"},{"key":"10","first-page":"4492","article-title":"Diffuse alveolar hemorrhage after erlotinib combined with concurrent chemoradiotherapy in a patient with esophageal carcinoma","volume":"7","author":"Xu","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/1477-7819-11-266","article-title":"Identification of exon 19 and 21 mutations of EGFR gene in Chinese patients with esophageal squamous cell carcinoma","volume":"11","author":"Gong","year":"2013","journal-title":"World J Surg Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12029-013-9511-9","article-title":"Curative treatment of esophageal cancer; an evidenced based review","volume":"44","author":"Thomas","year":"2013","journal-title":"J Gastrointest Cancer"},{"key":"13","first-page":"1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group","volume":"281","author":"Leichman","year":"1999","journal-title":"JAMA"},{"key":"14","first-page":"S253","article-title":"Current management of esophageal cancer","volume":"6","author":"Thomas","year":"2014","journal-title":"J Thorac Dis"},{"key":"15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1081\/CNV-120025092","article-title":"Paclitaxel and concurrent radiation in upper gastrointestinal cancers","volume":"21","author":"Safran","year":"2003","journal-title":"Cancer Invest"},{"key":"16","first-page":"CD003911","article-title":"Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma","volume":"5","author":"Bryant","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"17","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/annonc\/mdm004","article-title":"Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer","volume":"18","author":"Kelsen","year":"2007","journal-title":"Ann Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1016\/j.biomaterials.2013.07.100","article-title":"Epidermal growth factor receptor targeting in cancer: a review of trends and strategies","volume":"34","author":"Misra","year":"2013","journal-title":"Biomaterials"},{"key":"19","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1158\/0008-5472.CAN-04-3547","article-title":"Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)","volume":"65","author":"Harari","year":"2005","journal-title":"Cancer Res"},{"key":"20","first-page":"S47","article-title":"The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy","volume":"22","author":"Bianco","year":"2007","journal-title":"Cancer Res"},{"key":"21","first-page":"95","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study","volume":"1","author":"Bonner","year":"2006","journal-title":"Anticancer Drugs"},{"key":"22","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ijrobp.2009.10.012","article-title":"Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma","volume":"78","author":"Wu","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"23","doi-asserted-by":"crossref","first-page":"38429","DOI":"10.18632\/oncotarget.5193","article-title":"Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study","volume":"6","author":"Mao","year":"2015","journal-title":"Oncotarget"},{"key":"24","doi-asserted-by":"crossref","first-page":"26814","DOI":"10.18632\/oncotarget.4254","article-title":"A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives","volume":"6","author":"Adamo","year":"2015","journal-title":"Oncotarget"},{"key":"25","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nrc1953","article-title":"Integration of EGFR inhibitors with radiochemotherapy","volume":"6","author":"Lawrence","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.bjc.6604429","article-title":"Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancerorthotopic model","volume":"99","author":"Milano","year":"2008","journal-title":"Br J Cancer"},{"key":"27","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-04-2081","article-title":"Predictors of the response to gefitinib in refractory non-small cell lung cancer","volume":"11","author":"Park","year":"2005","journal-title":"Clin Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.lungcan.2008.11.006","article-title":"Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma","volume":"65","author":"Bang","year":"2009","journal-title":"Lung Cancer"},{"key":"29","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/tx900256y","article-title":"Bioactivation of the epidermal growth factor receptor inhibitor gefitinib:implications for pulmonary and hepatic toxicities","volume":"22","author":"Cameron","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"30","doi-asserted-by":"crossref","first-page":"e55128","DOI":"10.1371\/journal.pone.0055128","article-title":"Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"8","author":"Song","year":"2013","journal-title":"PLoS One"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T16:30:53Z","timestamp":1600705853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,3]]},"references-count":30,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2016,8,30]]}},"alternative-id":["9809","28087951"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.9809","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,3]]}}}